Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia

Blood

Volumn 91, Issue 10, 1998, Pages 3630-3636

  Barosi, Giovanni ^a   Ambrosetti, Achille ^b   Centra, Antonietta ^b   Falcone, Antonietta ^b   Finelli, Carlo ^b   Foa, Paolo ^b   Grossi, Alberto ^b   Guarnone, Roberta ^b   Rupoli, Serena ^b   Luciano, Luigiana ^b   Petti, Maria C ^b   Pogliani, Enrico ^b   Russo, Domenico ^b   Ruggeri, Marco ^b   Quaglini, Silvana ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLAST TRANSFORMATION; CHROMOSOME ABERRATION; COHORT ANALYSIS; DEATH; FEMALE; GENE DISRUPTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SPLENECTOMY; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; ITALY; LIFE TABLES; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; SPLENECTOMY;

EID: 18544413070     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Pitcock JA, Reinhard EH, Justus BW, Mendelsohn RS: A clinical and pathological study of seventy cases of myelofibrosis. Ann Intern Med 57:73, 1962
2. Bouroncle BA, Doan CA: Myelofibrosis: Clinical, hematologic and pathologic study of 110 patients. Am J Med Sci 243:697, 1962
3. Silverstein MN, Gomes MR, ReMine WH, Elvebach LR: Agnogenic myeloid metaplasia. Natural history and treatment. Arch Intern Med 120:546, 1967
4. Rosenthal DS, Moloney WC: Myeloid metaplasia. A study of 98 cases. Postgrad Med 45:136, 1969
5. Ward HP, Block MH: The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 50:357, 1971
6. Chelloul N, Briere J, Leval-Jeantet M, Najean Y, Vorhauer W, Jacquillat C: Prognostic of myeloid metaplasia with myelofibrosis. Biomedicine 24:272, 1976
7. Meytes D, Katz D, Ramot B: Prognostic parameters in myeloid metaplasia: Agnogenic vs post polycythaemia. Isr J Med Sci 12:534, 1976
8. Manoharan A, Smart RC, Pitney WR: Prognostic factors in myelofibrosis. Pathology 14:455, 1982
9. Varki A, Lottenberg R, Griffith R, Reinhard E: The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine 62:353, 1983
10. Lopez-Guillermo A, Cervantes F, Rovira M, Pereira A, Quinteros L, Rozman C: Myelofibrosis idiopatica: Patrones evolutivos, supervivencia y causas de muerte en una serie de 60 pacientes. Sangre 35:114, 1990
11. Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, Gianni L, Zuffa E, Aloe-Spiriti MA, Latagliata R, Pileri S, Magrini U, Gugliotta L, Morra E, Bernasconi C, Mandelli F, Tura S: Myelofibrosis with myeloid metaplasia: clinical and haematologic parameters predict-ing survival in a series of 133 patients. Br J Haematol 75:4, 1990
12. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F: Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88:1013, 1996
13. Bentley SA, Murray KH, Lewis SM, Roberts PD: Erythroid hypoplasia in myelofibrosis: A feature associated with blastic transformation. Br J Haematol 36:41, 1977
14. Barosi G, Baraldi A, Cazzola M, Spriano P, Magrini U: Red cell aplasia in myelofibrosis with myeloid metaplasia. Cancer 52:1290, 1983
15. Barosi G, Ambrosetti A, Buratti A, Finelli C, Liberate NL, Quaglini S, Ricetti MM, Visani G, Tura S, Ascari E: Splenectomy for patients with myelofibrosis with myeloid metaplasia. Pretreatment variables and outcome prediction. Leukemia 7:200, 1993
16. Lafaye F, Rain JD, Clot P, Najean Y: Risks and benefits of splenectomy in myelofibrosis: An analysis of 39 cases. Nouv Rev Fr Hematol 36:359, 1994
17. van Leeuwen FE, Somers R, Hart AAM: Splenectomy in Hodgkin's disease and second leukemias. Lancet 2:210, 1987
18. van der Velden JW, van Putten WLJ, Guinee VF, Pfeiffer R, van Leeuwen FE, van der Linden EA, Vardomskaya I, Lane W, Durand M, Lagarde C: Subsequent development of acute-nonlymphocytic leukemia in patients treated for Hodgkin's disease. Int J Cancer 42:252, 1988
19. van Leeuwen FE, Somers R, Taal BG, van Heerde P, Coster B, Dozeman T, Huisman SJ, Hart AA: Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol 7:1046, 1989
20. Meadows AT, Obringer AC, Marrero O, Oberlin O, Robison L, Fossati-Bellani F, Green D, Voute PA, Morris-Jones P, Greenberg M: Second malignant neoplasms following childhhood Hodgkin's disease: Treatment and splenectomy as risk factors. Med Pediatr Oncol 17:477, 1989
21. Kaldor JM, Day NE, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, Bell J, Pedersen D, Band P, Assouline D: Leukemia following Hodgkin's disease. N Engl J Med 322:7, 1990
22. Tura S, Fiacchini M, Zinzani PL, Brusamolino E, Gobbi PG: Splenectomy and the increasing risk of second acute leukemia in Hodgkin's disease. J Clin Oncol 11:925, 1993
23. Dietrich P-Y, Henry-Amar M, Cosset J-M, Bodis S, Bosq J, Hayat M: Second primary cancers in patients continuously disease-free from Hodgkin's disease: A protective role of the spleen. Blood 84:1209, 1994
24. Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, McCann SR, Frickhofen N, Van't Veer Korthof E, Gluckman E: Malignant tumor occurring after treatment of aplastic anemia. N Engl J Med 329:1152, 1993
25. Laszlo J: Myeloproliferative disorders (MPD): Myelofibrosis, myelosclerosis, extramedulllary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol 4:409, 1975
26. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
27. Cox DR: Regression models and life-tables. J R Stat Soc [B] 34:187, 1972
28. Schoenfeld D: Chi-squares goodness-of-fit tests for the proportional hazards regression model. Biometrika 67:145, 1980
29. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 70:41, 1983
30. Breiman L, Friedman JH, Olshen RA, Stone CJ: Classification and regression trees. Belmont, CA, Wadsworth International Group, 1984
31. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719, 1959
32. Drake C, Fosher L: Prognostic models and the propensity score. Int J Epidemiol 24:183, 1995
33. Muehleck SD, McKenna RW, Arthur DC, Parkin-JL, Brunning RD: Transformation of chronic myelogenous leukemia: Clinical, morphologic and cytogenetic features. Am J Clin Pathol 82:1, 1984
34. Andrieu J-M, Ifrah N, Payen C, Fermanian J, Coscas Y, Flandrin G: Increased risk of second acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 8:1148, 1990
35. Abrahamsen JF, Andersen A, Hannisdal E, Nome O, Abrahamsen AF, Kvaloy S, Host H: Second malignancies after tretament of Hodgkin's disease: The influence of treatment, follow-up time, and age. J Clin Oncol 11:255, 1993
36. Rodriguez MA, Fuller LM, Zimmerman SO, Allen PK, Brown BW, Munsell MF, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F Jr: Hodgkin's disease: Study of treatment intensities and incidences of second malignancies. Ann Oncol 4:125, 1993
37. van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt Dusebout AW, van Kerkhoff EH, van Heerde P, Somers R: Second cancer risk following Hodgkin's disease: A 20 year follow-up study. J Clin Oncol 12:312, 1994
38. Beaty O III, Hudson MM, Greenwald C, Luo X, Fang L, Wilimas JA, Thompson EI, Kun LE, Pratt CB: Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol 13:603, 1995
39. Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, Meadows AT: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334:745, 1996
40. Linet MS, Nyren O, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Adami HO, Fraumeni JF Jr: Risk of cancer following splenectomy. Int J Cancer 66:611, 1996
41. Robinette CD, Fraumeni JF Jr: Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet 2:127, 1977
42. Moloney WC, King VP: Reduction of leukemia incidence following splenectomy in the rat. Cancer Res 33:573, 1973
43. Nason-Burchenal K, Wolff L: Involvement of the spleen in preleukemic development of a murine retrovirus-induced promonocytic leukemia. Cancer Res 52:5317, 1992